Palvella Therapeutics, Inc. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Palvella Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2023-12-31 was $14.00K, a 84.95% decline year-over-year.
- Palvella Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2023-09-30 was $0.00.
- Palvella Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2023-06-30 was $52.00K, a 50.00% decline year-over-year.
- Palvella Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2022-12-31 was $93.00K, a 34.78% increase year-over-year.
- Palvella Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $66.00K, a 66.50% decline from fiscal 2022.
- Palvella Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $197.00K, a 19.39% increase from fiscal 2021.
- Palvella Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2021 was $165.00K, a 17.50% decline from fiscal 2020.
- Palvella Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2020 was $200.00K, a 45.80% decline from fiscal 2019.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2023-12-31 | $14.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $66.00K 10-K · filed 2024-03-29 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | |
| 2023-06-30 | $52.00K 10-Q · filed 2024-08-14 | |
| 2022-12-31 | $93.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $197.00K 10-K · filed 2024-03-29 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | |
| 2022-06-30 | $104.00K 10-Q · filed 2023-08-10 | |
| 2021-12-31 | $69.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $165.00K 10-K · filed 2023-03-31 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | |
| 2021-06-30 | $96.00K 10-Q · filed 2022-08-04 | |
| 2020-12-31 | $55.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | $200.00K 10-K · filed 2022-03-02 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | |
| 2020-06-30 | $145.00K 10-Q · filed 2021-08-05 | |
| 2019-12-31 | $191.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $369.00K 10-K · filed 2021-03-31 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | |
| 2019-06-30 | $178.00K 10-Q · filed 2020-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |